Delta-Fly Pharma (TSE:4598) EBITDA Margin %: 0.00% (As of Mar. 2026)


TSE:4598 Delta-Fly Pharma Inc TSE:4598
30 GF Score
Price 円135.00
! 2 Warning Signs
View Full Analysis

What is Delta-Fly Pharma EBITDA Margin %?

Delta-Fly Pharma TSE:4598 +2.27% 30 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates TSE:4598 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 936 Biotechnology companies, Delta-Fly Pharma ranks worse than 106837.5% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Delta-Fly Pharma's EBITDA for the six months ended in Mar. 2026 was 円-773.16 Mil. Delta-Fly Pharma's Revenue for the six months ended in Mar. 2026 was 円0.00 Mil. Therefore, Delta-Fly Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Delta-Fly Pharma  (TSE:4598) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Delta-Fly Pharma EBITDA Margin % Related Terms

Delta-Fly Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Delta-Fly Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delta-Fly Pharma EBITDA Margin % Chart

Delta-Fly Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -319.93 0.00 0.00 0.00 0.00

Delta-Fly Pharma Semi-Annual Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4598 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Delta-Fly Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Delta-Fly Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Delta-Fly Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Delta-Fly Pharma's EBITDA Margin % falls into.


TSE:4598
30GF Score
Delta-Fly Pharma Inc TSE:4598
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Delta-Fly Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Delta-Fly Pharma's EBITDA Margin % for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-1603.652/0
= %

Delta-Fly Pharma's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-773.155/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Delta-Fly Pharma (TSE:4598) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Delta-Fly Pharma and its competitors. According to the industry distribution chart, Delta-Fly Pharma ranks #999999 out of 936 companies in the Biotechnology industry.
Is Delta-Fly Pharma's EBITDA Margin % too high?
Delta-Fly Pharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, Delta-Fly Pharma ranks #999999 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Delta-Fly Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Delta-Fly Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Delta-Fly Pharma ranks #999999 out of 936 companies for EBITDA Margin %. This places Delta-Fly Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Delta-Fly Pharma and its competitors. Delta-Fly Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delta-Fly Pharma stock overvalued right now?
Delta-Fly Pharma (TSE:4598) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Delta-Fly Pharma's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Delta-Fly Pharma (TSE:4598), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Delta-Fly Pharma Business Description

Address 37-5, Miyajima Nishikino, Kawauchi-cho, Tokushima, JPN, 771-0116
Delta-Fly Pharma Inc is a Japan-based company mainly engaged in the discovery and development of gentle anti-cancer agents with module technology.
30GF Score

Get the complete analysis for TSE:4598

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円135.00
Price